Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

Autor: Nicole T. Vu, Stan Lightfoot, James R. Hocker, R. Jane Hanas, Harold M. Burkhart, Subrato J. Deb, Marvin D. Peyton, Jay S. Hanas, Megan R. Lerner, Min Li, Jess L. Thompson, Thomas C. Kupiec, Matthew Reinersman, Russell G. Postier, Stephen M. Dubinett, Daniel J. Brackett, Aurelien A. Quillet
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
Male
Proteomics
Cancer Research
medicine.medical_specialty
Stage I Non-Small Cell Lung Cancer
Lung Neoplasms
Adenocarcinoma of Lung
Adenocarcinoma
Tandem mass spectrometry
Diagnosis
Differential
03 medical and health sciences
0302 clinical medicine
Predictive Value of Tests
Tandem Mass Spectrometry
Internal medicine
Carcinoma
Non-Small-Cell Lung
medicine
Biomarkers
Tumor
Cell Adhesion
Humans
Lymphocytes
Lung cancer
Databases
Protein
Aged
Neoplasm Staging
Aged
80 and over
business.industry
Computational Biology
General Medicine
Middle Aged
Serum samples
medicine.disease
Phenotype
respiratory tract diseases
030104 developmental biology
030220 oncology & carcinogenesis
Case-Control Studies
Carcinoma
Squamous Cell
Protein identification
Female
Non small cell
business
Zdroj: Cancer investigation. 35(9)
ISSN: 1532-4192
Popis: A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje